West Pharmaceutical Services, Inc. (WST)

7 members of Congress have disclosed trading WST — 7 purchases and 3 sales worth an estimated $147,000. Most recent disclosure: Jun 17, 2025.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Company website ↗

• P/E ratio (47.0) — how many dollars you pay for each $1 of WST's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
• ROE (19.13%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
• Profit margin (16.85%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (0.25%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.